MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Further to our letter dated February 4, 2023, please be informed that Earnings Conference Call has been preponed to 3:30 P.M. (IST) (instead of 5:00 P.M.) on Tuesday, February 14, 2023. MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Credit Rating
Intimation of Credit Ratings of Marksans Pharma Limited by CARE Ratings Ltd. MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Q3FY23 Earnings Call. MARKSANS PHARMA LTD. - 524404 - Board Meeting Intimation for Notice Of Board Meeting
MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2023 ,inter alia, to consider and approve the Unaudited Financial Results of the Company (both Standalone and Consolidated) for the Quarter and Nine Months ended 31st December, 2022. MARKSANS PHARMA LTD. - 524404 - Submission Of Certificate From Statutory Auditor In Terms Of Regulation 169(5) Of The Securities And Exchange Board Of India (Issue Of Capital And Disclosure Requirements) Regulations, 2018
Submission of Certificate from Statutory Auditor in terms of Regulation 169(5) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Investors Meet MARKSANS PHARMA LTD. - 524404 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for OrbiMed Asia IV Mauritius FVCI Ltd MARKSANS PHARMA LTD. - 524404 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mark Saldanha & PACs MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Marksans Pharma Limited announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution. MARKSANS PHARMA LTD. - 524404 - Extinguishment Of Equity Shares Pursuant To Buyback
Details of Equity Shares extinguished by the Company are enclosed.